ISPOR - EE414 Incremental Costs of Abrocitinib Compared to Dupilumab for the Treatment of Moderate to Severe Atopic Dermatitis in Denmark

Full Text

EE414 Incremental Costs of Abrocitinib Compared to Dupilumab for the Treatment of Moderate to Severe Atopic Dermatitis in Denmark

Abstract

Authors

L. Sciera S.T. Gren D. Hauberg

Back to Volume 26, Supplemental Issue 12S

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now